Trial Profile

A Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CAL 101 Calluna Pharma (Primary)
Indications Idiopathic pulmonary fibrosis
Focus First in man; Therapeutic Use
Acronyms AURORA
Sponsors Calluna Pharma

Most Recent Events

27 Apr 2026 Planned End Date changed from 1 Nov 2027 to 1 Feb 2027.
27 Apr 2026 Planned primary completion date changed from 1 Aug 2027 to 1 Nov 2026.
27 Apr 2026 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com